IL6 and type 2 diabetes mellitus: Treatment with tocilizumab, an IL-6 receptor antibody, reduced proteinuria, and mesangial matrix accumulation in db/db mice, an experimental model of T2D [39].In patients with T2D, urinary IL-6 is associated with glomerular and tubular damage indicators [40].